NCT07846683

A Study to Assess the Efficacy and Safety of Subcutaneous Induction Therapy With Afimkibart in Participants With Moderately to Severely Active Ulcerative Colitis

RecruitingPHASE3INTERVENTIONAL

Trial Details

Start: 2026-11-15Est. Completion: 2028-05-31

Enrollment target: 350 participants

Locations

Contact

Reference Study ID Number: CA46523 https://forpatients.roche.com/ No attachments to email below.global-roche-genentech-trials@gene.com 888-662-6728 (U.S. and Canada)

Fastest response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry

Colitis, Ulcerative

The purpose of this study is to determine the safety, efficacy, and pharmacokinetics (PK) of etrasimod for the treatment…

Indianapolis, United StatesEst. completion Sep 8, 2030

Moderately to Severely Active Crohns Disease

This Phase III, multicenter, double-blind, placebo-controlled study will evaluate the efficacy and safety of induction t…

Dothan, United StatesEst. completion Dec 31, 2028

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.